Dashboard
Manage Tickers

EDIT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

barclays-maintains-equal-weight-on-editas-medicine-lowers-price-target-to-7
Barclays Maintains Equal-Weight on Editas ...
08/08/2024 18:44:28

Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $9 t...

truist-securities-maintains-buy-on-editas-medicine-lowers-price-target-to-12
Truist Securities Maintains Buy on Editas ...
08/08/2024 12:35:17

Truist Securities analyst Joon Lee maintains Editas Medicine (NASDAQ:EDIT) with a Buy and lowers the price target from $20 t...

boot-barn-to-rally-around-27-here-are-10-top-analyst-forecasts-for-thursday
Boot Barn To Rally Around 27%? Here Are 10...
08/08/2024 12:13:21

b-of-a-securities-upgrades-editas-medicine-to-buy-raises-price-target-to-15
B of A Securities Upgrades Editas Medicine...
08/08/2024 11:11:09

B of A Securities analyst Greg Harrison upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and raises the price targ...

editas-medicine-cash-balance-of-3183m-is-expected-to-provide-cash-runway-into-2026
Editas Medicine' Cash Balance Of $318.3M I...
08/07/2024 11:06:23

editas-medicine-q2-2024-gaap-eps-082-misses-070-estimate-sales-513000k-miss-5083m-estimate
Editas Medicine Q2 2024 GAAP EPS $(0.82) M...
08/07/2024 11:03:58

unveiling-5-analyst-insights-on-editas-medicine
Unveiling 5 Analyst Insights On Editas Med...
06/18/2024 17:00:48

oppenheimer-maintains-perform-on-editas-medicine-maintains-12-price-target
Oppenheimer Maintains Perform on Editas Me...
06/18/2024 16:46:34

Oppenheimer analyst Jay Olson maintains Editas Medicine (NASDAQ:EDIT) with a Perform and maintains $12 price target.

editas-medicine-unveils-updated-safety-and-efficacy-results-from-the-edithal-trial-of-reni-cel-in-7-patients-with-transfusion-dependent-beta-thalassemia-at-eha
Editas Medicine Unveils Updated Safety And...
06/14/2024 08:12:53

All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-fr...

editas-medicine-reveals-updated-safety-and-efficacy-results-from-the-ruby-trial-of-reni-cel-in-18-sickle-cell-patients-at-eha
Editas Medicine Reveals Updated Safety And...
06/14/2024 08:11:53

All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusi...

the-analyst-verdict-editas-medicine-in-the-eyes-of-4-experts
The Analyst Verdict: Editas Medicine In Th...
05/30/2024 16:00:14

evercore-isi-group-maintains-in-line-on-editas-medicine-lowers-price-target-to-7
Evercore ISI Group Maintains In-Line on Ed...
05/30/2024 15:14:49

Evercore ISI Group analyst Liisa Bayko maintains Editas Medicine (NASDAQ:EDIT) with a In-Line and lowers the price target fr...

editas-medicine-to-present-clinical-data-from-the-ruby-and-edithal-trials-of-reni-cel-at-the-eha-2024-congress-in-june
Editas Medicine To Present Clinical Data F...
05/14/2024 14:10:26

Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one o...

editas-medicine-reports-presentation-of-preclinical-data-demonstrating-several-in-vivo-capabilities-towards-developing-transformative-in-vivo-gene-editing-medicines
Editas Medicine Reports Presentation Of Pr...
05/10/2024 10:06:44

The Company will report these data later today in an oral presentation at Annual Meeting of the American Society of Gene and Ce...

citigroup-maintains-buy-on-editas-medicine-lowers-price-target-to-15
Citigroup Maintains Buy on Editas Medicine...
05/09/2024 18:05:16

Citigroup analyst Samantha Semenkow maintains Editas Medicine (NASDAQ:EDIT) with a Buy and lowers the price target from $16 ...

morgan-stanley-upgrades-editas-medicine-to-equal-weight-announces-7-price-target
Morgan Stanley Upgrades Editas Medicine to...
05/09/2024 16:41:38

Morgan Stanley analyst Matthew Harrison upgrades Editas Medicine (NASDAQ:EDIT) from Underweight to Equal-Weight and announce...

barclays-maintains-equal-weight-on-editas-medicine-lowers-price-target-to-9
Barclays Maintains Equal-Weight on Editas ...
05/09/2024 15:05:39

Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $11 ...

editas-medicine-q1-2024-adj-eps-076-misses-066-estimate
Editas Medicine Q1 2024 Adj EPS $(0.76) Mi...
05/08/2024 11:04:15

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0...

Core News & Articles
Editas Medicine Announced A Two-year Exten...
05/01/2024 12:09:34

Under the collaboration, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs...

editas-medicine-to-present-pre-clinical-data-demonstrating-progression-of-in-vivo-medicines-pipeline-at-american-society-of-gene-and-cell-therapy-annual-meeting
Editas Medicine To Present Pre-Clinical Da...
04/22/2024 20:33:55

Editas Medicine presentations at ASGCT include:Oral presentation of in vivo pre-clinical data from mouse studies using lipid na...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION